Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-300, MEK inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-300 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ARRY-300, MEK inhibitor; oral | DRUG | single dose, escalating |
| Placebo | DRUG | matching placebo |
Key Inclusion Criteria: * Healthy male or female (females must be of non-childbearing potential) between the ages of 18 and 50 years, inclusive. * Body mass index (BMI) of 18 kg/m2 to 35 kg/m2; and a total body weight \> 50 kg (110 lbs) and \< 113 kg (280 lbs). * Additional criteria exist. Key Exc...
ARRY-300 is an oral small molecule drug developed by Pfizer, Inc. (ticker PFE). It is an investigational compound that has been studied in a Phase 1 clinical trial in healthy subjects. Its therapeutic indications have not been disclosed.
ARRY-300 targets MET. It is classified as an inhibitor of this molecular target. By binding to MET, ARRY-300 acts as a small molecule inhibitor, though its specific clinical applications remain under investigation.
ARRY-300 is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the company responsible for the clinical development of this oral small molecule MET inhibitor.
ARRY-300 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes one completed trial evaluating its safety in healthy subjects.
ARRY-300 has been studied in one completed Phase 1 trial, NCT00828165, titled A Safety Study of ARRY-300 in Healthy Subjects. This randomized, double-blind, placebo-controlled trial enrolled 12 healthy adult volunteers in the United States.
ARRY-300 is also known as ARRY-300, MEK inhibitor, and is described as an oral formulation. These names refer to the same investigational compound developed by Pfizer. The MEK inhibitor designation reflects its classification as a small molecule inhibitor, though its stated molecular target is MET.